The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
The decision marks a pivotal moment for the Massachusetts-based biotech giant
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
